Hostname: page-component-78c5997874-g7gxr Total loading time: 0 Render date: 2024-11-13T01:49:44.321Z Has data issue: false hasContentIssue false
  • English
  • Français

Plasma Exchange of Malignant Multiple Sclerosis

Published online by Cambridge University Press:  18 September 2015

K.G. Warren ,
P.A. Gordon  and
T.A. McPherson
K.G. Warren*
Affiliation:
Department of Medicine and Laboratory Medicine (Division of Hematology), University of Alberta Hospital, 112 Street and 83 Avenue, Edmonton, Alberta, T6G 2B7
P.A. Gordon
Affiliation:
Department of Medicine and Laboratory Medicine (Division of Hematology), University of Alberta Hospital, 112 Street and 83 Avenue, Edmonton, Alberta, T6G 2B7
T.A. McPherson
Affiliation:
Department of Medicine and Laboratory Medicine (Division of Hematology), University of Alberta Hospital, 112 Street and 83 Avenue, Edmonton, Alberta, T6G 2B7
*
9-101 Clinical Sciences Building, University of Alberta, Edmonton, Alberta, T6G 2B7.
Rights & Permissions [Opens in a new window]

Summary:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

A 17-year old female with “malignant” multiple sclerosis died 45 weeks after the onset of the disease. Postmortem examination confirmed the clinical diagnosis of multiple sclerosis. After 30 weeks of rapid clinical progression, the patient was treated with two courses of plasma exchange therapy without immunosuppression. This form of therapy caused a drop in cerebrospinal fluid myelin basic protein levels in one instance, but not in another. Controlled clinical trials are required to determine whether plasma exchange therapy is of value in the management of patients with multiple sclerosis, and the monitoring of cerebrospinal fluid myelin basic protein, if elevated, may be one useful marker to follow as part of these studies.

Type
Research Article
Information
Canadian Journal of Neurological Sciences , Volume 9 , Issue 1 , February 1982 , pp. 27 - 30
Copyright
Copyright © Canadian Neurological Sciences Federation 1982

References

REFERENCES

Basten, A., Pollard, J.O., Stewart, G.J., Frith, J.A., McLeod, J.G., Walsh, J.C., Garrick, R., and Van DerBRINK, C.M. BRINK, C.M. (1980). Transfer factor in treatment of MS. Lancet, 2, 931–934.CrossRefGoogle Scholar
Dau, P.C., Petajan, J.H., Johnson, K.P., Panitch, J.S., and Bornstein, M.B. (1980). Plasmapheresis in multiple sclerosis: Preliminary findings. Neurology, 30, 1023–1028.CrossRefGoogle ScholarPubMed
Elsner, W., Tourtellotte, W.W., Murthy, K.M., Ma, B.I., Potvin, A.R., and Syndulko, K. (1978). Multiple Sclerosis: Effect of dexamethasone on in situ central nervous system IgG synthesis. Neurology, 28, 403–404.Google Scholar
Hsiung, H.M., Wu, J., and McPherson, T.A. (1978). Silica gel radioimmunoassay for myelin basic protein. Clin. Biochem., 11, 54–56.CrossRefGoogle ScholarPubMed
Jones, J.V., Clough, J.D., and Klimenberg, J.R. (1981). The role of therapeutic plasmapheresis in the rheumatic diseases. J. Lab. Clin. Med., 97, 589–598.Google ScholarPubMed
McAlpine, D., Lumsden, C.E., and Acheson, E.D. (1972). Multiple Sclerosis: A Reappraisal, 2nd edition p. 217. Churchill Livingstone, London.Google Scholar
Mertin, J., Knight, S.C., Rudge, P., Thompson, E.J., Healy, M.J.R. (1980). Double blind controlled trial of immunosuppression in the treatment of M.S. Lancet 2, 941–951.Google Scholar
Rothwell, R.S., Davis, P., Gordon, P.A., Dasgupta, M.K., Johny, K.V., Russell, A.S., and Percy, J.S. (1980). A controlled study of plasma exchange in the treatment of severe rheumatoid arthritis. Arthritis Rheum., 23, 785–790.CrossRefGoogle ScholarPubMed
Weiner, H.L., and Dawson, D.M. (1980). Plasmapheresis in multiple sclerosis: Preliminary study. Neurology, 30, 1029–1033.CrossRefGoogle ScholarPubMed
Whitaker, J.N., Lisak, R.P., Busher, B.M., Fitch, O.H., Seyer, J.M., Krance, R., Lawrence, J.A., Chien, L.T., and O’Sullivan, P. (1980). Immunoreactive myelin basic protein in the cerebrospinal fluid in neurological disorders. Annals Neurol., 7, 58–64.CrossRefGoogle ScholarPubMed